Endometrial cancer is the most commonly diagnosed female genital tract malignancy. Krü ppel-like factor 9 (KLF9), a member of the evolutionarily conserved Sp family of transcription factors, is expressed in uterine stroma and glandular epithelium, where it affects cellular proliferation, differentiation, and apoptosis. Deregulated expression of a number of Sp proteins has been associated with multiple types of human tumors, but a role for KLF9 in endometrial cancer development and/or progression is unknown. Here, we evaluated KLF9 expression in endometrial tumors and adjacent uninvolved endometrium of women with endometrial carcinoma. KLF9 mRNA and protein levels were lower in endometrial tumors coincident with decreased expression of family member KLF4 and growthregulators FBJ murine osteosarcoma viral oncogene homolog (FOS) and myelocytomatosis viral oncogene homolog (MYC) and with increased expression of telomerase reverse transcriptase (TERT) and the chromatin-modifying enzymes DNA methyltransferase 1 (DNMT1) and histone deacetylase 3 (HDAC3). Expression of estrogen receptor alpha (ESR1) and the tumorsuppressor phosphatase and tensin homolog deleted in chromosome 10 (PTEN) did not differ between tumor and normal tissue. The functional relevance of attenuated KLF9 expression in endometrial carcinogenesis was further evaluated in the human endometrial carcinoma cell line Ishikawa by siRNA targeting. KLF9 depletion resulted in loss of normal cellular response to the proliferative effects of estrogen concomitant with reductions in KLF4 and MYC and with enhancement of TERT and ESR1 gene expression. Silencing of KLF4 did not mimic the effects of silencing KLF9 in Ishikawa cells. We suggest that KLF9 loss-ofexpression accompanying endometrial carcinogenesis may predispose endometrial epithelial cells to mechanisms of escape from estrogen-mediated growth regulation, leading to progression of established neoplasms.
INTRODUCTION
Endometrial carcinoma (EC) is the most common gynecologic malignancy of women in the United States, with approximately 40 000 new cases and 8000 deaths reported in 2009 [1] . EC consists of two major histological subtypesnamely, the typically low-grade endometrioid EC (type I), which is associated with a favorable outcome, and the nonendometrioid EC (type II), which is high grade and correlated with poor prognosis. The estrogen-dependent type I EC develops from endometrial glands and accounts for approximately 80% of all cases. Risk factors for type I include early menarche, late menopause, nulliparity, obesity, and estrogen-only hormone replacement therapy [2] . Despite the fact that EC is readily treatable when diagnosed early, the mean 5-yr survival rate decreases by 70% when metastasis occurs [1] . Detection of atypical hyperplasia in endometrial biopsies is associated with increased risk of subsequent carcinoma; by contrast, simple hyperplasia and complex hyperplasia have low risk of progression and the potential for overdiagnosis and overtreatment [2] . Given the physical, emotional, and increasing financial burdens of EC and its potential misdiagnosis, the current detection and treatment paradigms for this disease could benefit from a continuing search to find new biomarkers for risk prediction.
The uterus, predominantly under the influence of the ovarian steroid hormones 17b-estradiol (estrogen [E 2 ]) and pregn-4-ene-3,20-dione (progesterone [P 4 ]), undergoes cycles of proliferation, differentiation, and apoptosis necessary to support its key reproductive function-namely, the implantation of a viable embryo leading to successful pregnancy [3] . E 2 and P 4 exert their actions by binding to cognate-receptors estrogen receptor-a and -b (ESR1 and ESR2) and progesterone receptors A and B (PGR-A and PGR-B), respectively [4, 5] . The actions of E 2 and P 4 leading to transcriptional activation of specific genes that modify cellular phenotype and behavior have resulted in a generalized molecular scheme for ESR and PGR signaling [4, 6] , but these pathways have become increasingly complex due to the participation of numerous nuclear coregulators, each of which demonstrates specific spatial and temporal expression and differentially affects ESR and PGR activities [7, 8] .
Our laboratory has identified the transcription factor Krüppel-like factor (KLF) 9, an Sp-family member [9] , as a transcriptional coregulator of ESR1 and PGR-B signaling in uterine cells [10] [11] [12] [13] [14] [15] . KLF9 is expressed in uterine endometrial stroma and glandular, but not luminal, epithelium in mice [16] , a finding recently confirmed for human endometrial cells [17] . Using mice null for KLF9 [16] , we demonstrated the numerous contributions of KLF9 to uterine morphology; embryo implantation, and fertility; sensitivity to E 2 and P 4 ; and timing of parturition [12, 14, 15, [18] [19] [20] . These findings have raised the possibility of yet unidentified roles for KLF9 in the etiology of gynecological diseases such as endometriosis and EC, which are characterized by unopposed E 2 signaling coincident with increased P 4 resistance. Notably, these findings also suggest the intriguing likelihood that KLF9 and/or its gene targets, the latter regulated in concert with PGR and ESR1, may serve as prognostic predictors for these uterine-associated diseases.
Initial studies from several groups, including our own, have suggested that KLF9 expression is attenuated or lost in human and mouse uterine endometriotic and EC tissues, EC cell lines, and human uterine leiomyoma [21] [22] [23] . Despite these findings, it remains unclear whether diminished KLF9 expression is causal to the manifestation of these diseases. The present study was designed to test the hypothesis that altered expression status of growth-regulatory genes is associated with aberrant KLF9 expression in EC. Using human EC tissue and cell line, we demonstrate that loss of KLF9 expression may predispose to mechanisms of escape from estrogen-mediated growth regulation to promote the progression of EC.
MATERIALS AND METHODS

Materials
Reagents were obtained from the following commercial sources: Dulbecco modified Eagle medium (DMEM), antibiotic-antimycotic (ABAM), Lipofectamine 2000 transfection reagent, OPTI-MEM I reduced serum medium, and TRIzol reagent from Invitrogen/GIBCO; Eagle minimum essential medium (MEM), dimethyl sulfoxide (DMSO), and E 2 from Sigma-Aldrich; fetal bovine serum (FBS) from Fisher Scientific; nontargeting (scrambled [Scr]), KLF9, and KLF4 siRNAs from Dharmacon, Inc.; MTT Cell Proliferation Assay Kit from American Type Culture Collection; and Caspase-Glo 3/7 Apoptosis Assay Kit from Promega Corp.
Biological Samples
Tissue samples were obtained from 13 patients recruited from a cohort of women diagnosed with EC and undergoing hysterectomy at the University of Arkansas for Medical Sciences (UAMS) between October 2009 and April 2010. Subject recruitment and related procedures for tissue harvest at surgery followed the protocol approved by the UAMS Institutional Review Board (IRB 11185). Inclusion criteria included age (25-75 yr) and no previous diagnosis of cancer. Risk-related information, such as age, parity, oral contraceptive pill use, body mass index (BMI), and in utero exposure to synthetic estrogens, was collected from each subject and considered in the data analyses. EC and surrounding nontumor (normal endometrium [NE]) tissues were excised by a surgical pathologist. Collected tissues were bisected and snap-frozen for subsequent molecular analyses. A portion of the EC for each subject was analyzed at the UAMS Pathology Core Laboratory as part of the routine cancer diagnosis, confirmation, grading, and staging.
Cell Culture and Treatments
The human EC cell line Ishikawa was maintained at 378C in an atmosphere of 5% CO 2 /95% air in flasks containing DMEM supplemented with 10% (v/v) FBS and 1% (v/v) ABAM (DMEM-FBS) [24] . For siRNA targeting studies, Ishikawa cells were seeded in six-well plates at a density of 6 DMSO (vehicle) or 100 nM E 2 in medium was performed for the indicated times as described for each experiment. Cell proliferation was measured as a function of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide oxidation (MTT Cell Proliferation Assay Kit), whereas apoptosis was measured as a function of caspase 3/7-facilitated luciferase activity (Caspase-Glo 3/7 Apoptosis Assay Kit), both following the manufacturer's instructions. Experiments were performed in quadruplicate (siRNA transfections) or quintuplicate (proliferation and apoptosis) on two or three separate occasions.
RNA Isolation, Quantitative RT-PCR, and Western Blot Analyses
Total RNA was isolated from uterine tissues or cells with TRIzol reagent following the manufacturer's protocol. RNA concentrations were determined using an ND-1000 spectrophotometer (Nanodrop). The cDNA was synthesized from 1 lg of total RNA using the Taqman Reverse Transcription Reagents Kit (Applied Biosystems) or the iScript cDNA Synthesis Kit (Bio-Rad), then analyzed by quantitative RT-PCR (QPCR) using SYBR Green (Bio-Rad) and the MyiQ optical module and iCycler thermal cycler (Bio-Rad) as previously described [24] . Intron-flanking primers (Table 1) were designed to eliminate the amplification of genomic DNA using Primer Express (Applied Biosystems) or PrimerQuest (Integrated DNA Technologies, Inc.) and were obtained from Integrated DNA Technologies, Inc. Western blot analyses were carried out as previously described [14, 20] using rabbit anti-rat KLF9 antibody [20] and antibodies against glyceraldehyde phosphate dehydrogenase (GAPDH; monoclonal anti-GAPDH; Sigma) and lamin A (Sigma) as loading controls.
Telomere Length Measurement
Telomere measurement was performed as previously described [25] . Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen). DNA (15 ng) was used in a 30-ll reaction containing SYBR Green (Bio-Rad) and the following primers: Tel A (5 0 -CGGTTTGTTTGGGTTT GGGTTTGGGTTTGGGTTTGGGTT-3 0 ) and Tel B (5 0 -GGCTTG CCTTACCCTTACCCTTACCCTTACCCTTACCCT-3 0 ). Primers A and B 
were used at a final concentration of 100 and 300 nM, respectively. Standards were generated by serial dilution of pooled DNA in the range of 15 to 0.469 ng.
Data Analysis
Statistical analyses were performed using SigmaStat (version 3.5; Systat Software). Data (mean 6 SEM) were analyzed for statistical significance (P 0.05) by two-way ANOVA followed by all pairwise multiple-comparison procedures (Tukey test) or Student t-test. Table 2 summarizes the demographic features of the women in the present study. The average age, age at menarche, and number of years of menstruation were 51 yr (range, 30-69 yr), 12 yr (range, 10-13 yr), and 35 yr (range, 19-47 yr), respectively. Only 1 of 13 women (7.7%) had a BMI within the normal range (BMI, [19] [20] [21] [22] [23] [24] , whereas the remainder (12/13, 92.3%) were classified as obese or extremely obese (BMI, .30). Nine of the 13 women had at least one successful delivery.
RESULTS
Demographic Information for Study Subjects
Reduced KLF9 Expression in EC
Endometrial tumors and adjacent tissues collected from women in the study were processed for hematoxylin-and-eosin (H&E) staining, and tumors were scored by grade and stage (Table 2) . Representative H&E-stained sections of normal and tumor tissues from two patients are shown in Figure 1A . Because of the small cohort size and most of the tumors (9/13) being grade 1, adjacent NE and EC tissues were collectively analyzed, irrespective of tumor stage and grade. Compared to NE tissues, EC tissues had decreased KLF9 transcript levels (by 50%; P ¼ 0.001) (Fig. 1B) . The reduction in transcript levels was confirmed at the protein level by Western blot analysis (Fig. 1C) . Densitometric quantification of the anti-KLF9 immunoreactive bands indicated significantly lower KLF9 protein in EC compared to NE (Fig. 1C) . Among family members, KLF4 transcript levels were down-regulated (P ¼ 0.03), but those for KLF13 were up-regulated (P ¼ 0.03), in EC relative to NE (Fig. 1B) . In contrast, KLF5 and KLF6 transcript levels did not differ with tumor status.
Changes in Expression of Growth-Associated Genes with Loss of KLF9 Expression in EC
To determine whether attenuated KLF9 expression in EC is associated with loss of growth control, the expression of a subset of growth-regulatory genes was evaluated in NE and EC by QPCR. We previously reported the aberrant expression of these genes in Klf 9-null mice with deregulated ESR1 signaling due to early postnatal exposure to diethylstilbestrol (DES) [15] . Loss of KLF9 expression in EC was accompanied by decreased expression of FBJ murine osteosarcoma viral oncogene homolog (FOS; P ¼ 0.03), a modest down-regulation of myelocytomatosis viral oncogene homolog (MYC; P ¼ 0.08), and a dramatic increase in telomerase reverse transcriptase (TERT; by 20-fold; P ¼ 0.02) transcript levels ( Fig. 2A) . ESR1 as well as phosphatase and tensin homolog deleted in chromosome 10 (PTEN) transcript levels were unchanged with carcinoma status. The increase in epithelial-specific cadherin (CDH1) transcript levels in EC relative to NE, which contrasts with the comparable transcript levels of stromal-specific vimentin (VIM) in EC and NE ( Fig. 2A) , is consistent with the higher glandular epithelial status associated with the transformation of NE to EC [2] .
Because altered expression of tumor-suppressor genes and oncogenes in cancer has been attributed in part to epigenetic mechanisms leading to gene silencing or activation, the expression of a number of chromatin-modifying enzymes were compared in NE and EC. The transcript levels of DNA methyltransferase 1 (DNMT1) and histone deacetylase 3 (HDAC3) were similarly up-regulated in EC relative to NE, whereas those for HDAC6 and HDAC9 were not different between tumor and nontumor endometria (Fig. 2B) .
The enhanced expression of TERT with EC ( Fig. 2A ) suggested elongated telomeres with EC status. However, no significant differences (P ¼ 0.45) in the mean telomere length (copy number) were observed between NE (14.88 6 2.99) and EC (11.99 6 2.24) tissues.
Expression of Growth-Regulatory Genes with KLF9 Knockdown
To evaluate the causal relationship between attenuated KLF9 expression in EC and the deregulated expression of growth-regulatory genes that might underlie the genesis and/or progression of endometrial carcinogenesis, siRNA targeting of KLF9 expression in Ishikawa human EC cells was performed. Cells were transfected with control Scr siRNA or siRNA directed against human KLF9 for 6 h and then treated with vehicle containing 100 nM E 2 for 72 h, the latter to mimic the high estrogenic environment of EC. Transcript levels for KLF9 and growth-regulatory genes (as described in Fig. 2A) were then measured by QPCR. Transfection of E 2 -treated cells with 
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KLF9 siRNA reduced KLF9 transcript levels by 60% (P , 0.001); this was accompanied by a greater than 90% loss of KLF9 protein, as determined by Western blot analyses of nuclear proteins from Scr siRNA-and KLF9 siRNA-transfected cells (Fig. 3, inset) . Attenuated KLF9 enhanced ESR1 (P ¼ 0.005), FOS (P ¼ 0.043), and TERT (P ¼ 0.004) expression; reduced KLF4 (P , 0.001) and MYC (P , 0.001) expression; and had no effect on KLF13 expression (Fig. 3) . The increase in ESR1 expression with KLF9 knockdown under conditions of high E 2 recapitulated that found for Ishikawa cells in a previous study [13] . Moreover, increased TERT expression (by ;2.5-fold) and decreased KLF4 and MYC expression with KLF9 siRNA targeting (Fig. 3 ) mimicked that observed in EC relative to NE (Fig. 2A) . However, the 2-fold increase in FOS expression and the lack of change in KLF13 expression with KLF9 knockdown relative to control siRNA-transfected cells differed from that observed in EC versus NE ( Fig. 2A) .
KLF9 Knockdown Effects on Cell Proliferation and Apoptosis
To directly link the loss of KLF9 regulation of growthregulatory genes in endometrial glands with disruption of cellular proliferation and apoptosis occurring with EC status [26] , control (vehicle alone) and E 2 -treated Ishikawa cells transfected with Scr or KLF9 siRNA were assayed for cell proliferation (MTT) and apoptosis (induction of caspase3/7 activity) after 72 h. As expected, E 2 treatment increased cell proliferation in cells normally expressing KLF9 (P ¼ 0.04) (Fig. 4A) . KLF9 knockdown in non-E 2 -treated cells increased   FIG. 1 . Analyses of KLF9 expression in human EC tissues. A) Representative H&E-stained sections of adjacent NE and EC tissues from two patients undergoing hysterectomy after diagnosis with EC. GE, glandular epithelium; LE, luminal epithelium; ST, stroma. Original magnification 310. B) Messenger RNA transcript levels of KLF9 and KLF family members were quantified by QPCR and normalized to those of TATA box-binding protein (TBP). Data (mean 6 SEM) are expressed as the foldchange relative to corresponding NE (n ¼ 13 samples/tissue type). C) Western blot analyses of nuclear proteins isolated from NE and EC tissues using rabbit anti-rat KLF9 and anti-GAPDH (loading control) antibodies. A representative blot (left) with the quantified data from densitometric scans of normalized immunoreactive bands from NE and EC samples pooled from individual patients (right) is shown. *P , 0.05 (Student t-test).
KLF9 IN ENDOMETRIAL CARCINOMA proliferation (P ¼ 0.03) to the same extent as that found for E 2 -treated, KLF9-expressing cells. However, the number of epithelial cells upon E 2 -treatment was decreased with KLF9 knockdown, suggesting the loss of normal proliferative response to E 2 of cells lacking KLF9 (Fig. 3B) . Cellular apoptosis was disrupted by KLF9 knockdown but only in the background of high E 2 (Fig. 4B) . Notably, a modest but significant decrease in apoptosis (P , 0.05) was observed under estrogenic conditions in cells lacking KLF9, which was not observed in KLF9-expressing cells.
KLF4 Effects on KLF9-Regulated Genes
Given the coincident loss of KLF4 and KLF9 expression in EC (Fig. 1B) and in Ishikawa cells under a background of high E 2 (Fig. 3) , we determined whether KLF4 mediates KLF9 regulation of MYC and TERT gene expression, which was decreased and increased, respectively, with loss of KLF9 expression (Fig. 2) . Ishikawa cells were transfected with Scr siRNA or siRNA targeting KLF4 and then treated with E 2 (100 nM). Transfection with KLF4 siRNA resulted in a significant reduction (by 60%; P , 0.001) of KLF4 expression (Fig. 5) . The transcript levels of KLF9 and other genes for which expression were altered in EC versus NE (see Fig. 2 ) were quantified in Ishikawa cells transfected with either control (Scr) siRNA or siRNA directed against KLF9 and treated with vehicle (0.1% DMSO in treatment medium; data not shown) or 100 nM E 2 in vehicle for 72 h. Data (mean 6 SEM) were normalized to TBP and are expressed as the foldchange relative to vehicle-treated, scRNA-transfected controls (n ¼ 4 individual wells/transfection). Inset) KLF9 knockdown resulted in more than 90% loss of KLF9 protein levels. *P , 0.05 (Student t-test) .
FIG. 4. Proliferative and apoptotic responses of human Ishikawa cells to
KLF9 gene silencing. A) Proliferation status of Ishikawa cells transfected with either Scr or KLF9 siRNAs and treated with vehicle (0.1% DMSO in treatment medium) or 100 nM E 2 was measured using the MTT assay after 3 days. Data (mean 6 SEM) are from five independent experiments. B) Apoptotic status of Ishikawa cells transfected with either Scr or KLF9 siRNAs and treated with vehicle (0.1% DMSO in treatment medium) or 100 nM E 2 for 72 h was measured using the caspase 3/7-Luciferase assay kit and expressed as relative light units (RLUs). Data (mean 6 SEM) are from five independent experiments. Means with different letters differed significantly (P , 0.05, two-way ANOVA followed by Tukey test).
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However, both MYC and TERT expression were unaffected by KLF4 knockdown.
DISCUSSION
Previous reports have shown KLF9 to influence the transcription of PGR-and ESR1-regulated genes [10, 11, 13, 15] , to mediate cell-cycle component expression [27] , and to control cell proliferation and apoptosis [18, 27] . Female mice mutant for Klf9 exhibited subfertility [12] and delayed onset of parturition [19] , resulting in part from defective PGR signaling. Moreover, endometriosis, a P 4 -resistant condition, was associated with loss of KLF9 expression in eutopic endometrium of an experimental mouse model of endometriosis [22] . To further understand how disruptions in steroid hormone receptor coregulator functions may lead to uterine pathology, we examined whether KLF9 expression is deregulated in EC and, if so, whether this is linked to loss of normal growth regulation of endometrial epithelial cells. We found that KLF9 mRNA and protein levels were significantly attenuated in EC relative to NE. The loss of KLF9 expression likely reflects a true down-regulation rather than a change in the proportion of KLF9-expressing cells between EC and NE, given the higher glandular epithelial status associated with the transformation of NE to EC [2] . Notably, the loss of KLF9 expression was accompanied by increased expression of TERT, KLF13, DNMT1, and HDAC3 and decreased expression of FOS, KLF4, and MYC. By using the human EC cell line Ishikawa, we confirmed KLF9-mediated up-regulation of TERT and down-regulation of KLF4 and MYC expression by silencing KLF9 in glandular epithelial cells under a high-estrogenic environment, mimicking that found in EC. The lack of confirmatory responses in vitro of KLF13 (no change) and FOS (increased rather than decreased) gene expression and the dramatic induction in ESR1 expression with KLF9 silencing in Ishikawa cells likely reflect the distinct, cumulative effects of KLF9 loss-ofexpression in whole endometrial tissue as opposed to isolated glandular epithelial cells. In this regard, whereas KLF13 is predominantly expressed in endometrial stromal cells [20] , FOS and ESR1 are ubiquitously expressed in all endometrial cell types. Finally, we showed, to our knowledge for the first time, the existence in endometrial glandular epithelial cells of a regulatory link between KLF9 and KLF4 on one hand and between KLF9 and TERT on the other, which has important implications for growth control.
Our studies identified KLF4 and TERT as candidate KLF9 downstream targets by which KLF9 may contribute to the progression of endometrial carcinogenesis. To our knowledge, this is the first report of decreased KLF4 expression in EC. KLF4 functions as a prodifferentiation and antiproliferative protein [28] and is a downstream target [29] as well as a transcriptional repressor [30] of the tumor-suppressor p53. KLF4 has also been reported to inhibit oncogene WNT signaling by interacting with b-catenin, thus disrupting bcatenin-mediated recruitment of the coactivators p300/CBP [31] . KLF9 regulation of KLF4 expression aligns with our previous findings showing that forced overexpression of KLF9 in the human EC HEC-1A cells resulted in increased KLF4 transcript levels [21] . The coincident down-regulation of KLF4 and KLF9 has also been reported in human colorectal cancer [32, 33] . Together, these findings raise the intriguing possibility of interactions of KLF9, through its regulation of KLF4, with p53 (TP53) and WNT signaling pathways, both of which are deregulated in cancer, and may offer important clues for understanding the contribution of KLF9 to growth regulation.
Of particular interest is the negative correlation between KLF9 and TERT expression in EC and in E 2 -treated Ishikawa cells, consistent with our previous report of enhanced Tert expression in uteri of Klf9-null mice upon deregulation of uterine Esr1 signaling because of early postnatal exposure to DES [15] . TERT encodes the telomerase gene transcriptase, which constitutes the catalytic subunit of the telomerase holoenzyme [34] . Previous studies have shown that a strong association exists between TERT transcript levels and telomerase activity [34, 35] , that TERT expression specifically correlates with cell proliferation [36] , and that TERT activity is increased in human EC relative to the normal cycling endometrium [37] [38] [39] . Furthermore, an E 2 -dependent, ESR1-facilitated increase in TERT has been reported in various tissues [40] [41] [42] . The latter raises the possibility that the observed increase in ESR1 expression with KLF9 siRNA targeting in glandular epithelial cells [13] (present study) underlies enhanced TERT expression, providing a common pathway by which KLF9 and ESR1 mediate endometrial TERT expression. In addition, given the role for TERT in promoting progression of established neoplasms [43] , our data also suggest a mechanism by which KLF9 loss-of-expression may promote a cellular context favoring tumorigenesis. The lack of the coincident increase in telomere length with increased telomerase activity in EC relative to NE is in keeping with mounting evidence for telomere length-independent pathways of growth stimulation by TERT [44, 45] .
The coincident loss of KLF9 and KLF4 with increased TERT expression suggests a transcriptional cross-regulatory network between these KLFs and TERT, as reported in mouse embryonic fibroblasts wherein Tert overexpression resulted in the coincident down-regulation of Klf4 and Klf9 expression [36] . However, KLF4 knockdown in Ishikawa cells failed to elicit TERT up-regulation, identical to that found with KLF9 knockdown, indicating distinct cell typespecific programs of gene regulation. Furthermore, attenuated KLF4 expression had no effect on KLF9 expression (data not shown). Thus, in the hierarchy of KLF family crossregulation, KLF9 may occupy a higher ''seat,'' given that it also influences the expression of KLF13 [20] as well as KLF5 and KLF6 (data not shown), albeit under different endometrial cell contexts.
Several other findings from the present study are novel and worth noting. First, KLF9 knockdown in E 2 -treated Ishikawa cells resulted in the loss of normal epithelial response to E 2 (i.e., increased proliferation). The decrease in glandular cell numbers observed by blocking KLF9 expression is in agreement with our previous finding of lower gland numbers, but increased gland sizes, in DES-exposed uteri from Klf9-null mice compared to those of KLF9-expressing (wild-type) mice [15] . In keeping with the association of resistance to apoptosis with tumorigenicity, we found a modest, albeit significant, decrease in apoptotic status of E 2 -treated cells upon KLF9 knockdown. Second, despite reports that PTEN is one of the most frequently altered genes in EC [46, 47] , we did not find a correlation between PTEN expression and EC status in the present study. Whereas the latter may be related to the small sample size and the use of adjacent (nontumor) tissues as control for EC tissues in the present study, our results are consistent with those in a recent report suggesting loss of PTEN expression as an unreliable marker of progression to EC [48] . Nevertheless, because forced expression of PTEN in PTEN-null Ishikawa cells was found to inhibit TERT expression [49] , early loss of endometrial PTEN expression may facilitate neoplastic transformation in part by enhancing TERT expression, similar to the effect elicited by KLF loss. Third, the increased expression of the chromatin-modifying enzymes DNMT1 and HDAC3 in EC is consistent with the reported epigenetic deregulation in EC [50] . Indeed, aberrant promoter methylation of PGR [51] and of the WNT-inhibitor adenomatosis polyposis coli [52] in EC had been proposed as possible mechanisms for alterations in gene expression noted with this disease. Finally, the positive association of obesity and incidence of EC, a well-established phenomenon based on epidemiological studies [53] in our patient cohort with loss of endometrial KLF9 expression, is intriguing given the recent report implicating KLF9 in adipogenesis [54] . Our collective data raise the possibility that KLF9-promoter silencing, consequent to the deregulated expression of a number of chromatin-modifying enzymes, may facilitate the progression of EC. Future studies at the level of the KLF9 promoter will address this predicted mechanism.
In summary, using a subset of previously identified growthassociated genes for which expression was altered in uteri of Klf9 mice with dysregulated Esr1 signaling [15] to query EC and NE tissues, we have provided support for the functional relevance of KLF9 to human EC. We suggest that KLF9 as well as its downstream targets KLF4 and TERT may function as novel predictors/diagnostic markers of EC status. Future work utilizing a larger cohort of patients as well as further exploration of the role of KLF9 in glandular epithelial biology will expand our current understanding of the regulatory grid mediated by KLF9 in the pathogenesis of EC and, perhaps, other reproductive diseases.
